MA26557A1 - Determination du caractere anormal de croissance cellulaire - Google Patents

Determination du caractere anormal de croissance cellulaire

Info

Publication number
MA26557A1
MA26557A1 MA25308A MA25308A MA26557A1 MA 26557 A1 MA26557 A1 MA 26557A1 MA 25308 A MA25308 A MA 25308A MA 25308 A MA25308 A MA 25308A MA 26557 A1 MA26557 A1 MA 26557A1
Authority
MA
Morocco
Prior art keywords
cell growth
proteins
determination
growth abnormalities
cancerous
Prior art date
Application number
MA25308A
Other languages
English (en)
Inventor
Haydn Williams Gareth
Coleman Nicholas
Alfred Laskey Ronald
Original Assignee
Cancer Res Compaign Technology
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9722217.8A external-priority patent/GB9722217D0/en
Priority claimed from GBGB9724134.3A external-priority patent/GB9724134D0/en
Priority claimed from GBGB9804156.9A external-priority patent/GB9804156D0/en
Priority claimed from GBGB9810560.4A external-priority patent/GB9810560D0/en
Priority claimed from GBGB9817075.6A external-priority patent/GB9817075D0/en
Application filed by Cancer Res Compaign Technology filed Critical Cancer Res Compaign Technology
Publication of MA26557A1 publication Critical patent/MA26557A1/fr

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57411—Specifically defined cancers of cervix
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57496—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving intracellular compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Oncology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Measurement And Recording Of Electrical Phenomena And Electrical Characteristics Of The Living Body (AREA)
  • Measuring And Recording Apparatus For Diagnosis (AREA)
  • Electrotherapy Devices (AREA)
  • Investigating Or Analysing Materials By Optical Means (AREA)
  • Peptides Or Proteins (AREA)
  • Eye Examination Apparatus (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Liquid Crystal Substances (AREA)
MA25308A 1997-10-21 1998-10-21 Determination du caractere anormal de croissance cellulaire MA26557A1 (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GBGB9722217.8A GB9722217D0 (en) 1997-10-21 1997-10-21 Determination of cellular growth abnormality
GBGB9724134.3A GB9724134D0 (en) 1997-11-14 1997-11-14 Determination of cellular growth abnormality
GBGB9804156.9A GB9804156D0 (en) 1998-02-26 1998-02-26 Determination of cellular growth abnormality
GBGB9810560.4A GB9810560D0 (en) 1998-05-15 1998-05-15 Determination of cellular growth abnormality
GBGB9817075.6A GB9817075D0 (en) 1998-08-05 1998-08-05 Determination of cellular growth abnormality

Publications (1)

Publication Number Publication Date
MA26557A1 true MA26557A1 (fr) 2004-12-20

Family

ID=27517431

Family Applications (1)

Application Number Title Priority Date Filing Date
MA25308A MA26557A1 (fr) 1997-10-21 1998-10-21 Determination du caractere anormal de croissance cellulaire

Country Status (23)

Country Link
EP (1) EP1025444B1 (fr)
JP (2) JP2000511291A (fr)
CN (1) CN1282422A (fr)
AT (1) ATE290213T1 (fr)
AU (1) AU751754B2 (fr)
BR (1) BR9813127A (fr)
CA (1) CA2305872C (fr)
CO (1) CO5080817A1 (fr)
DE (1) DE69829198T2 (fr)
DK (1) DK1025444T3 (fr)
ES (1) ES2239407T3 (fr)
GB (1) GB2332515B (fr)
HU (1) HUP0004134A2 (fr)
IL (1) IL135602A0 (fr)
IS (1) IS5456A (fr)
MA (1) MA26557A1 (fr)
NO (1) NO20002044L (fr)
NZ (1) NZ503996A (fr)
PE (1) PE20000121A1 (fr)
PL (1) PL340057A1 (fr)
PT (1) PT1025444E (fr)
SK (1) SK5592000A3 (fr)
WO (1) WO1999021014A1 (fr)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6361954B1 (en) 1996-05-02 2002-03-26 Cold Spring Harbor Laboratory Methods of immunoassay for human CDC6
GB0018140D0 (en) * 2000-07-24 2000-09-13 Medical Res Council Screening for abnormalities
DE10063179A1 (de) * 2000-12-18 2002-06-20 Bayer Ag Verfahren zur spezifischen Detektion von Tumorzellen und ihren Vorstufen in Gebärmutterhalsabstrichen durch simultane Messung von mindestens zwei verschiedenen molekularen Markern
DE10063112A1 (de) 2000-12-18 2002-06-20 Bayer Ag Verfahren zur Erhöhung der klinischen Spezifität bei der Detektion von Tumoren und ihren Vorstufen durch simultane Messung von mindestens zwei verschiedenen molekularen Markern
EP1373896A2 (fr) 2001-03-12 2004-01-02 MonoGen, Inc. Detection et differenciation d'etats pathologiques par echantillons cellulaires
EP1369694A1 (fr) 2002-04-09 2003-12-10 MTM Laboratories AG Procédé de discrimination entre des métaplasies et des lésions néoplastiques ou préneoplastiques
EP2311978A1 (fr) * 2002-08-20 2011-04-20 Millennium Pharmaceuticals, Inc. Compositions, kits et procédés d'identification, évaluation, prévention et thérapie du cancer du col de lutérus
EP1422526A1 (fr) 2002-10-28 2004-05-26 MTM Laboratories AG Procédé ameliorée de diagnostic des dysplasies
US20070015154A1 (en) * 2003-02-14 2007-01-18 Smithkline Beecham Corporation Differentially expressed nucleic acids that correlate with ksp expression
US7361460B2 (en) 2003-04-11 2008-04-22 Digene Corporation Approach to molecular diagnosis of human papillomavirus-related diseases
EP1688503A4 (fr) * 2003-10-20 2007-10-31 Sysmex Corp Methode de traitement de cellules
CN1957256B (zh) * 2004-03-24 2013-01-02 三路影像公司 用于子宫颈疾病检测的方法和组合物
US7595380B2 (en) * 2005-04-27 2009-09-29 Tripath Imaging, Inc. Monoclonal antibodies and methods for their use in the detection of cervical disease
GB0518877D0 (en) * 2005-09-15 2005-10-26 Medical Res Council Markers and methods
US7632498B2 (en) 2005-12-19 2009-12-15 Tripath Imaging, Inc. MCM6 and MCM7 monoclonal antibodies and methods for their use in the detection of cervical disease
ES2545119T3 (es) 2006-01-05 2015-09-08 The Ohio State University Research Foundation Métodos basados en microARN y composiciones para el diagnóstico y el tratamiento de cánceres sólidos
US7985584B2 (en) 2006-03-20 2011-07-26 The Ohio State University Research Foundation MicroRNA fingerprints during human megakaryocytopoiesis
DE102006020852A1 (de) 2006-05-04 2007-11-15 Robert Bosch Gmbh Gasdruckbehälter für gasbetriebene Kraftfahrzeuge
CN101835902B (zh) 2007-08-03 2014-03-26 俄亥俄州立大学研究基金会 编码ncrna的超保守区域
GB0811567D0 (en) * 2008-06-24 2008-07-30 Cytosystems Ltd Assay
AU2010321555B2 (en) 2009-11-23 2015-10-15 The Ohio State University Materials and methods useful for affecting tumor cell growth, migration and invasion
GB0921873D0 (en) * 2009-12-15 2010-01-27 Cytosystems Ltd Assay
CA2816603A1 (fr) 2010-11-12 2012-05-18 The Ohio State University Research Foundation Materiaux et procedes relatifs aux microarn-21, reparation de desappariement et cancer colorectal
AU2011329066B2 (en) 2010-11-15 2017-03-09 The Ohio State University Research Foundation Controlled release mucoadhesive systems
WO2012090479A1 (fr) * 2010-12-28 2012-07-05 Oncotherapy Science, Inc. Mcm7 comme gène cible pour la thérapie anticancéreuse et le diagnostic du cancer
CA2852066A1 (fr) 2011-10-14 2013-04-18 The Ohio State University Methodes et materiaux relatifs au cancer des ovaires
AU2012352265B2 (en) 2011-12-13 2017-02-16 Ohio State Innovation Foundation Methods and compositions related to miR-21 and miR-29a, exosome inhibition, and cancer metastasis
EP2800821B1 (fr) * 2012-01-05 2016-11-16 Centre National de la Recherche Scientifique (CNRS) Signature pour le diagnostic de l'agressivité du cancer du poumon
EP2804960A4 (fr) 2012-01-20 2015-08-19 Univ Ohio State Signatures de marqueurs biologiques du cancer du sein concernant le pouvoir envahissant et le pronostic
US11306364B2 (en) 2012-02-18 2022-04-19 Duke University TERT promoter mutations in gliomas and a subset of tumors
KR101832948B1 (ko) * 2013-02-18 2018-02-28 듀크 유니버시티 신경교종 및 종양의 서브세트 내 tert 프로모터 돌연변이
GB201412731D0 (en) * 2014-07-17 2014-09-03 Immunocore Ltd & Adaptimmune Ltd Peptides
EP3295173A1 (fr) * 2015-05-10 2018-03-21 Ventana Medical Systems, Inc. Compositions et procédés pour l'inactivation simultanée des enzymes de phosphatase alcaline et de peroxydase au cours de dosages de coloration tissulaire multiplex automatisés
ES2911415T3 (es) 2015-06-08 2022-05-19 Arquer Diagnostics Ltd Métodos y kits
US11519916B2 (en) 2015-06-08 2022-12-06 Arquer Diagnostics Limited Methods for analysing a urine sample
GB201509907D0 (en) * 2015-06-08 2015-07-22 Urosens Ltd Antibodies
GB201511196D0 (en) 2015-06-25 2015-08-12 Cytosystems Ltd Monoclonal antibodies
JP6245299B2 (ja) * 2016-04-27 2017-12-13 バクスアルタ ゲーエムベーハー 組換え安定細胞クローン、その産生およびその使用
CN106636343B (zh) * 2016-11-04 2021-03-19 深圳大学 一种检测口腔癌的标志物及其试剂盒
GB201820867D0 (en) * 2018-12-20 2019-02-06 Arquer Diagnostics Ltd Detection method
CN115453108A (zh) * 2019-12-11 2022-12-09 广东菲鹏生物有限公司 用于免疫诊断试剂中固相载体的封闭阶段处理剂及应用和产品

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK144485A (da) * 1984-03-30 1985-10-01 Syntex Inc Monoklonale antistoffer
US5851821A (en) * 1996-05-02 1998-12-22 Cold Spring Harbor Laboratory DNA Replication-regulating genes
EP0812594A1 (fr) * 1996-06-13 1997-12-17 BOEHRINGER INGELHEIM INTERNATIONAL GmbH Composés interférant avec la réplication de l'ADN dans les cellules proliférant rapidement pour l'utilisation dans la thérapie des cancers, et méthodes pour identifier ces composés
US5858683A (en) * 1996-08-30 1999-01-12 Matritech, Inc. Methods and compositions for the detection of cervical cancer

Also Published As

Publication number Publication date
AU751754B2 (en) 2002-08-29
CA2305872C (fr) 2008-02-19
BR9813127A (pt) 2000-08-15
CO5080817A1 (es) 2001-09-25
AU9550298A (en) 1999-05-10
GB9823069D0 (en) 1998-12-16
NO20002044D0 (no) 2000-04-18
DE69829198T2 (de) 2006-01-12
DK1025444T3 (da) 2005-06-27
WO1999021014A1 (fr) 1999-04-29
JP2000511291A (ja) 2000-08-29
PE20000121A1 (es) 2000-02-17
JP3774196B2 (ja) 2006-05-10
NZ503996A (en) 2002-04-26
PL340057A1 (en) 2001-01-15
EP1025444B1 (fr) 2005-03-02
HUP0004134A2 (en) 2001-03-28
EP1025444A1 (fr) 2000-08-09
DE69829198D1 (de) 2005-04-07
IS5456A (is) 2000-04-17
SK5592000A3 (en) 2000-10-09
PT1025444E (pt) 2005-07-29
CN1282422A (zh) 2001-01-31
GB2332515A (en) 1999-06-23
CA2305872A1 (fr) 1999-04-29
IL135602A0 (en) 2001-05-20
GB2332515B (en) 1999-12-15
ATE290213T1 (de) 2005-03-15
ES2239407T3 (es) 2005-09-16
NO20002044L (no) 2000-06-07
JP2003240786A (ja) 2003-08-27

Similar Documents

Publication Publication Date Title
MA26557A1 (fr) Determination du caractere anormal de croissance cellulaire
Garewal et al. Reduced bile acid-induced apoptosis in “normal” colorectal mucosa: a potential biological marker for cancer risk
AU2006200645B2 (en) Nuclear matrix protein alterations associated with colon cancer and colon metastasis to the liver, and uses thereof
Komiya et al. p21 expression as a predictor for favorable prognosis in squamous cell carcinoma of the lung.
AU2002246970B2 (en) Detection of survivin in the biological fluids of cancer patients
DE69717664D1 (de) Protein e25a, methoden zu dessen herstellung und anwendung
CA2487048A1 (fr) Procede de diagnostic a base de solution
DK0507852T3 (da) Gen deleteret hos mennesker med kolorektal cancer
AU2003214909A1 (en) Nuclear matrix protein alterations associated with colon cancer and colon metastasis to the liver, and uses thereof
Testori et al. Primary melanoma: from history to actual debates
AP2000001917A0 (en) Gene encoding labyrinthin, a marker for cancer.
DK0566571T3 (da) Diagnose af metastatisk cancer ved hjælp af mts-1-genet
Reis Filho et al. p63 expression in sarcomatoid/metaplastic carcinomas of the breast
AR014382A1 (es) Determinacion de anormalidad en el crecimiento celular
TH41035B (th) การกำหนดของความผิดปกติในการเจริญเติบโตของเซลล์
TH41035A (th) การกำหนดของความผิดปกติในการเจริญเติบโตของเซลล์
Gupta et al. Tissue isoantigens A, B, and H in carcinoma of the cervix uteri: their clinical significance
Yildirim et al. Significance of p53 and bcl-2 immunoexpression in the prognosis of laryngeal squamous cell carcinoma
Ye et al. Study on the different expression of molecular markers between cardiac cancer and distal gastric cancer and their correlations with clinicopathological features
Freeman Potential clinical applications of antibodies against the minichromosome maintenance (MCM) proteins
Pujol et al. Long term survival after pulmonary resection for small cell carcinoma of the lung.
Wundrack et al. PCR Expression Analysis Of the Estrogeninducible Gene Bcei in Gastrointestinal and Other Human Tumors
Veale et al. Pulmonary haemorrhage in Henoch-Schonlein purpura.
EP1243653A3 (fr) Protéine E25a, procédés de production et utilization
Wild et al. canccr (NscLc) andupeciallythc ssuewrusctllsubtype,(2) toasscss